Genomic Health Inc. provided earnings guidance for the fourth quarter and full year of 2016. The company expects revenue in the fourth quarter of 2016 to be approximately $84 million, leading to a double-digit growth. The company’s gross margin rate was 84.1% in the third quarter, reflecting the change in license fees for PCR. The company anticipates gross margin rates to remain in this range in the coming quarters. The company expects approximately 14% revenue growth for the year 2016, consistent with the midpoint of full year guidance. The company expects to achieve full year operating leverage goal of approximately 40% in 2016. That is $0.40 of improved operating income for every new revenue dollar when compared to 2015, leading to net loss for the year that is consistent with the midpoint of full year guidance.